Prasad’s FDA appointment pressures cell and gene therapy stocks

Biotech stocks fall on Vinay Prasad news

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Biotech was not faring well yesterday, after we got the news that Vinay Prasad was chosen to be the next director of the FDA’s biologics center.Read the rest…

Prasad’s FDA appointment pressures cell and gene therapy stocks

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.

Biotech Stocks Slide After FDA Selects Prasad to Lead CBER

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised concerns over regulatory scrutiny as the biotech market dropped.

Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment

How did biopharma stocks react to Vinay Prasad’s appointment as director of one of the FDA's top jobs? Not well. Prasad, a hematologist-oncologist by training who gained prominence for criticizing the FDA and former NIAID ...

Sarepta shares fall amid FDA's CBER appointment and weak Elevidys sales - Pharmaceutical Technology

Sarepta’s stock dropped by 26% after the FDA named a vocal critic of its gene therapy programme to lead its biologics division.

Vinay Prasad to Replace Peter Marks in Genetic Medicine Review Office

Vinay Prasad will assume leadership of the office respo […] The post Vinay Prasad to Replace Peter Marks in Genetic Medicine Review Office first appeared on GeneOnline News. The post Vinay Prasad to Replace Peter Marks in Genetic Medicine Review Office appeared first on GeneOnline News.